PDS Biotechnology Corporation

NASDAQ:PDSB

Biotechnology

Healthcare
$0.92 +1.21%

+$0.01 today

Market cap
$51.58M
Beta
1.56
P/E (TTM)
-1.5
EPS (TTM)
-$0.60
52W Low $0.51High $1.67

Volume 5.25M

Average 1.04M

PDSB Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

PDS Biotechnology CorporationNASDAQ: PDSB

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of $6.52M fell 28.4% year over year, behind the -18.0% change in trailing-twelve-month operating expenses. Sequentially, it fell 2.3% from the prior quarter. Over 3 fiscal years it compounded at -8.9% a year.

Context

  • Operating expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -28.4% toward the trailing-twelve-month pace of -18.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.52M-2.3% QoQ
Last fiscal yearDec 2025
$31.54M-13.0% YoY
LTMMar 2026
$28.96M-18.0% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.4%——
1 year-13.0%——
3-year CAGR-8.9%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
31.54M USD
Year-over-year change
-13.0%
4-year CAGR
+10.1%

Operating Expenses vs competitors

How PDSB compares with its peers on the latest reported figures

  • PDSB's LTM Mar 2026 operating expenses of $28.96M is the 5th highest of the 6 companies compared; the peer median is $43.18M.
  • Its year-over-year change of -18.0% is the 5th highest of 6, against a peer median of +3.9%.
  • Over three fiscal years its annual growth of -8.9% compares with a peer median of +5.2%.
PDSB Competitors Peer median
Operating Expenses for PDSB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XLOXilio Therapeutics, Inc.LTM Mar 2026$80.05M +20.9%-1.9%149.7%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$61.36M -12.1%+27.8%—
INMBINmune Bio, Inc.LTM Mar 2026$43.18M +3.9%+5.5%—
ANVSAnnovis Bio, Inc.LTM Mar 2026$41.42M +64.6%+5.2%—
PDSBPDS Biotechnology CorporationLTM Mar 2026$28.96M -18.0%-8.9%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$25.93M -40.9%+1.1%73.9%
Peer median (excluding PDSB) $43.18M+3.9%+5.2%111.8%

Competitors are the stored peer set for PDSB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0057.33K59.79K0
Gross Profit00(57.33K)(59.79K)0
Gross Margin—————
Research & Development11.25M29.43M27.76M22.57M19.03M
Selling, General & Admin10.18M12.24M15.28M13.7M12.52M
Operating Expenses21.44M41.67M43.05M36.26M31.54M
Depreciation & Amortization5.36K8657.33K59.79K21.84K
EBITDA(21.43M)(40.74M)(40.09M)(33.75M)(30.3M)
EBITDA Margin—————
Operating Income(21.44M)(41.67M)(43.05M)(36.32M)(31.54M)
Operating Margin—————
Interest Income4.35K935.18K2.9M2.52M1.22M
Interest Expense01.32M4.21M4.67M5.34M
Other Income / Expenses4.35K(381.34K)(1.3M)(2.16M)(4.12M)
Income Before Tax(21.43M)(42.05M)(44.35M)(38.48M)(35.67M)
Pre-Tax Margin—————
Income Tax Expense(4.52M)(1.2M)(1.41M)(869.17K)(1.17M)
Net Income(16.92M)(40.85M)(42.94M)(37.61M)(34.5M)
Net Margin—————
EPS (Basic)(0.66)(1.43)(1.39)(1.03)(0.74)
EPS (Diluted)(0.66)(1.43)(1.39)(1.03)(0.74)
Weighted Avg Shares25.6M28.6M30.95M36.45M46.38M
Weighted Avg Shares (Diluted)25.6M28.6M30.95M36.45M46.38M

PDS Biotechnology Corporation

NASDAQ:PDSB

Intrinsic Alpha fair value

Locked

Current Price

$0.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.